%0 Journal Article
%A Nuñez-Gil, Ivan J
%A Fernandez-Perez, Cristina
%A Estrada, Vicente
%A Becerra-Muñoz, Victor M
%A El-Battrawy, Ibrahim
%A Uribarri, Aitor
%A Fernandez-Rozas, Inmaculada
%A Feltes, Gisela
%A Viana-Llamas, Maria C
%A Trabattoni, Daniela
%A Lopez-Pais, Javier
%A Pepe, Martino
%A Romero, Rodolfo
%A Castro-Mejia, Alex F
%A Cerrato, Enrico
%A Astrua, Thamar Capel
%A D'Ascenzo, Fabrizio
%A Fabregat-Andres, Oscar
%A Moreu, Jose
%A Guerra, Federico
%A Signes-Costa, Jaime
%A Marin, Francisco
%A Buosenso, Danilo
%A Bardaji, Alfredo
%A Raposeiras-Roubin, Sergio
%A Elola, Javier
%A Molino, Angel
%A Gomez-Doblas, Juan J
%A Abumayyaleh, Mohammad
%A Aparisi, Alvaro
%A Molina, Maria
%A Guerri, Asuncion
%A Arroyo-Espliguero, Ramon
%A Assanelli, Emilio
%A Mapelli, Massimo
%A Garcia-Acuña, Jose M
%A Brindicci, Gaetano
%A Manzone, Edoardo
%A Ortega-Armas, Maria E
%A Bianco, Matteo
%A Trung, Chinh Pham
%A Nuñez, Maria Jose
%A Castellanos-Lluch, Carmen
%A Garcia-Vazquez, Elisa
%A Cabello-Clotet, Noemi
%A Jamhour-Chelh, Karim
%A Tellez, Maria J
%A Fernandez-Ortiz, Antonio
%A Macaya, Carlos
%T Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.
%D 2020
%U http://hdl.handle.net/10668/16570
%X Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation  0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-ORhydroxychloroquine 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-ORantiviral 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399.
%K COVID-19
%K Mortality
%K Prognosis
%K Registry
%K Score
%~